TSS
VYNE icon

Two Sigma Securities’s VYNE Therapeutics VYNE Stock Holding History

Two Sigma Securities’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,050
Closed -$2.83K – 3334
2022
Q4 		$2.83K Buy
+1,050
New +$4.2K ﹤0.01% 2494
2022
Q3 		– Sell
-7,102
Closed -$50K – 3154
2022
Q2 		$50K Buy
+7,102
New +$59.6K ﹤0.01% 1847
2022
Q1 		– Sell
-2,638
Closed -$48K – 2552
2021
Q4 		$48K Buy
+2,638
New +$56.6K ﹤0.01% 1281

Other funds holding VYNE

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Two Sigma Securities's VYNE Position: Q1 2023 in Review

Two Sigma Securities sold out of VYNE Therapeutics (VYNE) in Q1 2023, closing a stake of 1,050 shares — an estimated $2.83K sold.

Two Sigma Securities first reported a position in VYNE in Q4 2021 and held it in 3 quarters. The position peaked at $50K in Q2 2022. 23 funds tracked by Wall St. Rank hold VYNE as of Q1 2023.

  • Two Sigma Securities reported no remaining VYNE Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Two Sigma Securities sold 1,050 VYNE Therapeutics shares in Q1 2023, an estimated $2.83K.
  • Two Sigma Securities first reported a position in VYNE Therapeutics in Q4 2021 and held it in 3 quarters.
  • Two Sigma Securities's VYNE Therapeutics position peaked at $50K in Q2 2022.
  • 23 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2023.

Based on Two Sigma Securities's 13F filing for Q1 2023, filed 15 May 2023.